{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:05:25Z","timestamp":1789689925278,"version":"4.0.1"},"reference-count":63,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2014,12,5]],"date-time":"2014-12-05T00:00:00Z","timestamp":1417737600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0114398","type":"journal-article","created":{"date-parts":[[2014,12,5]],"date-time":"2014-12-05T23:59:37Z","timestamp":1417823977000},"page":"e114398","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":37,"title":["MYC Protein Expression in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System"],"prefix":"10.1371","volume":"9","author":[{"given":"Kamraan Z.","family":"Gill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashleigh","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Hoehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vundavalli V.","family":"Murty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bachir","family":"Alobeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Govind","family":"Bhagat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,12,5]]},"reference":[{"key":"ref1","unstructured":"Swerdlow SH, International Agency for Research on Cancer, World Health Organization (2008) WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer. 439 p. p."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/archneurol.2010.3","article-title":"Primary central nervous system lymphoma","volume":"67","author":"ER Gerstner","year":"2010","journal-title":"Arch Neurol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00401-013-1202-x","article-title":"Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice","volume":"127","author":"M Deckert","year":"2014","journal-title":"Acta Neuropathol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/sj.leu.2405019","article-title":"Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell","volume":"22","author":"M Montesinos-Rongen","year":"2008","journal-title":"Leukemia"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cell.2012.03.003","article-title":"MYC on the path to cancer","volume":"149","author":"CV Dang","year":"2012","journal-title":"Cell"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/1750-9378-8-37","article-title":"MYC chromosomal aberration in differential diagnosis between Burkitt and other aggressive lymphomas","volume":"8","author":"G Aquino","year":"2013","journal-title":"Infect Agent Cancer"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1038\/leu.2008.230","article-title":"Structural aberrations affecting the MYC locus indicate a poor prognosis independent of clinical risk factors in diffuse large B-cell lymphomas treated within randomized trials of the German High-Grade Non-Hodgkin&apos;s Lymphoma Study Group (DSHNHL)","volume":"22","author":"W Klapper","year":"2008","journal-title":"Leukemia"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1002\/cncr.27396","article-title":"Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab","volume":"118","author":"N Akyurek","year":"2012","journal-title":"Cancer"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s11899-013-0169-y","article-title":"The impact of MYC rearrangements and &quot;double hit&quot; abnormalities in diffuse large B-cell lymphoma","volume":"8","author":"P Lin","year":"2013","journal-title":"Curr Hematol Malig Rep"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, <etal>et al<\/etal>. (2013) MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121: 4021\u20134031; quiz 4250","DOI":"10.1182\/blood-2012-10-460063"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.12763","article-title":"MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"165","author":"AM Perry","year":"2014","journal-title":"Br J Haematol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"NA Johnson","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00401-013-1169-7","article-title":"Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC(low)BCL2 (low) subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas","volume":"126","author":"A Brunn","year":"2013","journal-title":"Acta Neuropathol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"4814","DOI":"10.1200\/JCO.2008.16.1455","article-title":"Del(6)(q22) and BCL6 rearrangements in primary CNS lymphoma are indicators of an aggressive clinical course","volume":"26","author":"FM Cady","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1182\/blood-2003-05-1465","article-title":"Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation","volume":"103","author":"M Montesinos-Rongen","year":"2004","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2005-03-0897","article-title":"Gene expression and angiotropism in primary CNS lymphoma","volume":"107","author":"JL Rubenstein","year":"2006","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"208","DOI":"10.5858\/2003-127-208-EOPMOB","article-title":"Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals","volume":"127","author":"CC Chang","year":"2003","journal-title":"Arch Pathol Lab Med"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s004010050831","article-title":"Expression of oncogenic molecules in primary central nervous system lymphomas in immunocompetent patients","volume":"95","author":"M Nozaki","year":"1998","journal-title":"Acta Neuropathol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"CP Hans","year":"2004","journal-title":"Blood"},{"key":"ref20","unstructured":"International Standing Committee on Human Cytogenetic Nomenclature, Shaffer LG, Slovak ML, Campbell LJ (2009) ISCN 2009 : an international system for human cytogenetic nomenclature (2009). Basel; Unionville, CT: Karger. vi, 138 p., 131 folded leave p."},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"TM Green","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1200\/JCO.2003.09.139","article-title":"Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience","volume":"21","author":"AJ Ferreri","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1084\/jem.20091071","article-title":"Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia","volume":"207","author":"L Jones","year":"2010","journal-title":"J Exp Med"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"5203","DOI":"10.1158\/1078-0432.CCR-12-0845","article-title":"Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas","volume":"18","author":"A Gonzalez-Aguilar","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1158\/1078-0432.CCR-11-0395","article-title":"Primary central nervous system lymphomas: a validation study of array-based comparative genomic hybridization in formalin-fixed paraffin-embedded tumor specimens","volume":"17","author":"E Braggio","year":"2011","journal-title":"Clin Cancer Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1182\/blood-2010-07-297861","article-title":"Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma","volume":"117","author":"CO Sung","year":"2011","journal-title":"Blood"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00401-010-0709-7","article-title":"Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma","volume":"120","author":"M Montesinos-Rongen","year":"2010","journal-title":"Acta Neuropathol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/leu.2013.348","article-title":"High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma","volume":"28","author":"W Kraan","year":"2014","journal-title":"Leukemia"},{"key":"ref29","unstructured":"Bretones G, Delgado MD, Leon J (2014) Myc and cell cycle control. Biochim Biophys Acta."},{"key":"ref30","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a014241","article-title":"MYC Activation Is a Hallmark of Cancer Initiation and Maintenance","volume":"4","author":"M Gabay","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref31","article-title":"MicroRNAs as regulators and mediators of c-MYC function","author":"R Jackstadt","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"ref32","article-title":"The activities of MYC, MNT and the MAX-interactome in lymphocyte proliferation and oncogenesis","author":"JM Link","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"ref33","article-title":"MYC and the Art of MicroRNA Maintenance","author":"JN Psathas","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/ncb2024","article-title":"miR-9, a MYC\/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis","volume":"12","author":"L Ma","year":"2010","journal-title":"Nat Cell Biol"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1073\/pnas.0808042106","article-title":"p53 represses c-Myc through induction of the tumor suppressor miR-145","volume":"106","author":"M Sachdeva","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/neuonc\/nor107","article-title":"Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas","volume":"13","author":"L Fischer","year":"2011","journal-title":"Neuro Oncol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1038\/sj.onc.1202749","article-title":"Mysterious liaisons: the relationship between c-Myc and the cell cycle","volume":"18","author":"AJ Obaya","year":"1999","journal-title":"Oncogene"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1038\/sj.onc.1202751","article-title":"The role of c-myc in cellular growth control","volume":"18","author":"EV Schmidt","year":"1999","journal-title":"Oncogene"},{"key":"ref39","article-title":"Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP","author":"A Tzankov","year":"2013","journal-title":"Mod Pathol"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1182\/blood-2005-03-1024","article-title":"A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases","volume":"107","author":"S Camilleri-Broet","year":"2006","journal-title":"Blood"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/cncr.23149","article-title":"Bcl-6 predicts improved prognosis in primary central nervous system lymphoma","volume":"112","author":"O Levy","year":"2008","journal-title":"Cancer"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"e98169","DOI":"10.1371\/journal.pone.0098169","article-title":"Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma","volume":"9","author":"C Bellas","year":"2014","journal-title":"PLoS One"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1750-3639.2000.tb00244.x","article-title":"Characteristic chromosomal imbalances in primary central nervous system lymphomas of the diffuse large B-cell type","volume":"10","author":"T Weber","year":"2000","journal-title":"Brain Pathol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5414\/NPP27013","article-title":"Activated B-cell immunophenotype might be associated with poor prognosis of primary central nervous system lymphomas","volume":"27","author":"S Bhagavathi","year":"2008","journal-title":"Clin Neuropathol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/modpathol.2009.164","article-title":"Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases","volume":"23","author":"EM Hattab","year":"2010","journal-title":"Mod Pathol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/j.1440-1789.2009.01074.x","article-title":"Primary central nervous system lymphoma: immunohistochemical profile and prognostic significance","volume":"30","author":"D Raoux","year":"2010","journal-title":"Neuropathology"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"PN Meyer","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1212\/WNL.0b013e31820f2d94","article-title":"Rituximab monotherapy for patients with recurrent primary CNS lymphoma","volume":"76","author":"TT Batchelor","year":"2011","journal-title":"Neurology"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/neuonc\/not032","article-title":"Rituximab is associated with improved survival for aggressive B cell CNS lymphoma","volume":"15","author":"G Gregory","year":"2013","journal-title":"Neuro Oncol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s12094-007-0086-4","article-title":"Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule","volume":"9","author":"M Santisteban","year":"2007","journal-title":"Clin Transl Oncol"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Wong ET (2005) Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 64: 934; author reply 934.","DOI":"10.1212\/WNL.64.5.934"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1093\/neuonc\/not012","article-title":"Prognostic significance of the aggregative perivascular growth pattern of tumor cells in primary central nervous system diffuse large B-cell lymphoma","volume":"15","author":"M He","year":"2013","journal-title":"Neuro Oncol"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-2141.2007.06661.x","article-title":"Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas","volume":"138","author":"M Ponzoni","year":"2007","journal-title":"Br J Haematol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s11060-007-9363-x","article-title":"Angiogenesis in primary central nervous system lymphoma (PCNSL)","volume":"84","author":"H Takeuchi","year":"2007","journal-title":"J Neurooncol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11060-006-9281-3","article-title":"Endoglin (CD 105) is expressed on endothelial cells in the primary central nervous system lymphomas and correlates with survival","volume":"82","author":"Y Sugita","year":"2007","journal-title":"J Neurooncol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1111\/j.1365-2141.2007.06929.x","article-title":"Endothelial hyperplasia and endothelial galectin-3 expression are prognostic factors in primary central nervous system lymphomas","volume":"140","author":"N D'Haene","year":"2008","journal-title":"Br J Haematol"},{"key":"ref57","first-page":"1063","article-title":"BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma","volume":"9","author":"KM Braaten","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/bjh.12801","article-title":"LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma","volume":"165","author":"C Lossos","year":"2014","journal-title":"Br J Haematol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s11060-011-0555-z","article-title":"Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma","volume":"104","author":"MK Song","year":"2011","journal-title":"J Neurooncol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/1078-0432.CCR-05-1699","article-title":"Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin","volume":"12","author":"CH Lin","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11060-009-0078-z","article-title":"Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma","volume":"98","author":"H Momota","year":"2010","journal-title":"J Neurooncol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1200\/JCO.2012.46.9957","article-title":"Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)","volume":"31","author":"JL Rubenstein","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1002\/cncr.21481","article-title":"Trends in survival from primary central nervous system lymphoma, 1975-1999: a population-based analysis","volume":"104","author":"KS Panageas","year":"2005","journal-title":"Cancer"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0114398","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,23]],"date-time":"2022-04-23T23:31:41Z","timestamp":1650756701000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0114398"}},"subtitle":[],"editor":[{"given":"Renato","family":"Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,12,5]]},"references-count":63,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,12,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0114398","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,5]]}}}